Meeting
2023 ASCO Genitourinary Cancers Symposium
Trial in progress: PRESTIGE—Primary retroperitoneal lymph node dissection (RPLND) for clinical stage II (CSII) testicular germ cell tumour (TGCT) and its impact on health-related quality of life (HRQoL) compared to chemotherapy or radiotherapy.
Authors
Ciara Conduit
Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
Ciara Conduit , Jeremy Howard Lewin , Elizabeth Chien Hern Liow , Haryana M. Dhillon , Wei Hong , Richard De Abreu Lourenço , Nathan Lawrentschuk , Benjamin Thomas , Peter S. Grimison , Nariman Ahmadi , Shomik Sengupta , Ben Tran
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr TPS433)
DOI
10.1200/JCO.2023.41.6_suppl.TPS433
Abstract #
TPS433
Poster Bd #
N15
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
EDEN (Etude Désescalade sEmiNome): Prospective therapeutic de-escalation and miRNA-M371 biomarker evaluation phase II study for stage IIa/IIb < 3 cm seminomas.
First Author: Armelle Vinceneux
Poster
2012 Genitourinary Cancers Symposium
Long-term outcomes of radiotherapy for stage II testicular seminoma: The Mayo Clinic experience.
First Author: Christopher Leigh Hallemeier
Poster
2023 ASCO Genitourinary Cancers Symposium
Trial in progress: PREPARE—Exploring the activity of pseudoephedrine in treating retrograde ejaculation following retroperitoneal lymph node dissection (RPLND) in survivors of testicular cancer (TC).
First Author: Ciara Conduit
Poster
2022 ASCO Genitourinary Cancers Symposium
The PRIMETEST trial: Prospective phase II trial of primary retroperitoneal lymph node dissection (RPLND) in stage II A/B patients with seminoma.
First Author: Peter Albers